primary antibodies against mouse cd206  (Cell Signaling Technology Inc)

Journal: Frontiers in Bioengineering and Biotechnology

Article Title: An engineered adipose formulation decreases hepatic inflammation and fibrosis in a rodent model of metabolic dysfunction-associated steatotic liver disease

doi: 10.3389/fbioe.2025.1579062

Figure Lengend Snippet: Effects of mAF treatment on hepatic macrophages in CGI-58 LivKO mice. (A) Representative IHC images and quantification of the (B) M1 macrophage marker CD68, (C) M2 macrophage marker CD206, and (D) ratio of CD68 to CD206 in the liver of mice. Data are presented as mean ± SD. n = 8 for treatment group, and n = 3 for ALB- group. *P < 0.05, **P < 0.01 by Student’s t-test. Scale bars: 50 μm.

Article Snippet: The expression of CD68 and CD206 in the liver was evaluated by immunohistochemical staining using primary antibodies against mouse CD68 (1:4,000 dilution, Abcam, Waltham, MA) or mouse CD206 (1:1,600 dilution, Cell Signaling Technology ® , Danvers, MA).

Techniques: Marker

Journal: Journal of neuroinflammation

Article Title: Development of cerebral microhemorrhages in a mouse model of hypertension.

doi: 10.1186/s12974-025-03378-7

Figure Lengend Snippet: Fig. 9 CD206 immunoreactivity is unaffected by Ang II and is significantly reduced by PLX3397 diet. (A) Images showing CD206 immunofluorescence, indicative of perivascular macrophages. Scale bar = 50 µm. (B) Ang II infusion does not affect CD206 immunoreactivity, while PLX3397 diet significantly reduces CD206 immunoreactivity. (C) In animals with and without Ang II-induced hypertension (PBS-CTL and AngII-CTL), the number of CMH was positively correlated with Iba-1 immunoreactivity (r = 0.51). A nonsignificant (p = 0.35) association was observed between CD206 immunoreactivity and CMH number per cm2. Data shown are mean ± SEM. n = 3–5 per sex per group. ***p < 0.001 and ****p < 0.0001

Article Snippet: For CD206 (to detect perivascular macrophages), we used 10% donkey serum as a blocking agent for 1 h at room temperature, incubated with rat primary antibodies against CD206 (macrophage marker) (Bio-Rad Laboratories, Hercules, CA, USA) at 1:500 dilution overnight at 4 °C, washed with PBST, and then incubated with antirat IgG secondary antibody (Thermo Fisher Scientific, Waltham, MA, USA) at 1:200 dilution for 1 h at room temperature.

Techniques: Immunofluorescence